Skip to main content
SpringerLink
Log in

Clinical Features of Metastatic Hepatic Malignancies

  • Chapter
  • First Online:
Gastrointestinal Malignancies

Part of the book series: Cancer Treatment and Research ((CTAR))

Abstract

The liver is a common site for gastrointestinal tumor metastases as it is the first major organ reached by blood draining the portal venous system. With the development of more effective chemotherapeutic agents which may eradicate residual microscopic disease in the liver and help reduce known tumor burden, partial hepatectomy to remove gross metastatic disease will likely become increasingly utilized in the future. This chapter discusses the presentation and clinical factors in liver directed surgical resection.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jarnagin WR et al (1999) Liver resection for metastatic colorectal cancer: assessing the risk of occult irresectable disease. J Am Coll Surg 188(1):33–42

    Article  CAS  PubMed  Google Scholar 

  2. Cancer Facts and Figures (2006) American Cancer Society

    Google Scholar 

  3. Choti MA et al (1998) Should hepatic resections be performed at high-volume referral centers? J Gastrointest Surg 2(1):11–20

    Article  CAS  PubMed  Google Scholar 

  4. Fong Y, Blumgart LH (1998) Hepatic colorectal metastasis: current status of surgical therapy. Oncology (Williston Park) 12(10): 1489–1498 (discussion 1498-500, 1503)

    Google Scholar 

  5. Jarnagin WR et al (2002) Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg 236(4): 397–406 (discussion 406-7)

    Google Scholar 

  6. Adam R et al (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8(4):347–353

    Article  CAS  PubMed  Google Scholar 

  7. Alberts SR et al (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23(36):9243–9249

    Article  CAS  PubMed  Google Scholar 

  8. Folprecht G et al (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17(3):450–456

    Article  CAS  PubMed  Google Scholar 

  9. Giacchetti S et al (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10(6):663–669

    Article  CAS  PubMed  Google Scholar 

  10. Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342

    Article  CAS  PubMed  Google Scholar 

  11. Masi G et al (2006) Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 13(1):58–65

    Article  PubMed  Google Scholar 

  12. Pozzo C et al (2004) Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 15(6):933–939

    Article  CAS  PubMed  Google Scholar 

  13. Tournigand C et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol 24(3):394–400

    Article  CAS  PubMed  Google Scholar 

  14. Bengmark S, Hafstrom L (1969) The natural history of primary and secondary malignant tumors of the liver. II. The prognosis for patients with hepatic metastases from gastric carcinoma verified by laparotomy and postmortem examination. Digestion 2(3):179–186

    Article  CAS  PubMed  Google Scholar 

  15. Bengtsson G et al (1981) Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 141(5):586–589

    Article  CAS  PubMed  Google Scholar 

  16. de Brauw LM et al (1987) Diagnostic evaluation and survival analysis of colorectal cancer patients with liver metastases. J Surg Oncol 34(2):81–86

    Article  PubMed  Google Scholar 

  17. Goslin R et al (1982) Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum 25(8):749–754

    Article  CAS  PubMed  Google Scholar 

  18. Jaffe BM et al (1968) Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet 127(1):1–11

    CAS  PubMed  Google Scholar 

  19. Lewis AM, Martin RC (2006) The treatment of hepatic metastases in colorectal carcinoma. Am Surg 72(6):466–473

    PubMed  Google Scholar 

  20. Finan PJ et al (1985) Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis. Br J Surg 72(5):373–377

    Article  CAS  PubMed  Google Scholar 

  21. Wood CB, Gillis CR, Blumgart LH (1976) A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 2(3):285–288

    CAS  PubMed  Google Scholar 

  22. Stangl R et al (1994) Factors influencing the natural history of colorectal liver metastases. Lancet 343(8910):1405–1410

    Article  CAS  PubMed  Google Scholar 

  23. Vassiliades VG, Foley WD, Alarcon J et al (1991) Hepatic metastases: CT versus MR imaging at 1.5T. Gastrointest Radiol 16:159–163

    Article  CAS  PubMed  Google Scholar 

  24. Kronawitter U et al (1999) Evaluation of chest computed tomography in the staging of patients with potentially resectable liver metastases from colorectal carcinoma. Cancer 86(2):229–235

    Article  CAS  PubMed  Google Scholar 

  25. Povoski SP et al (1998) Role of chest CT in patients with negative chest x-rays referred for hepatic colorectal metastases. Ann Surg Oncol 5(1):9–15

    Article  CAS  PubMed  Google Scholar 

  26. Bernatik T et al (2001) Detection of liver metastases: comparison of contrast-enhanced wide-band harmonic imaging with conventional ultrasonography. J Ultrasound Med 20(5):509–515

    CAS  PubMed  Google Scholar 

  27. Fong Y et al (1999) Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 178(4):282–287

    Article  CAS  PubMed  Google Scholar 

  28. Akhurst T et al (2005) Recent chemotherapy reduces the sensitivity of [18F] fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 23(34):8713–8716

    Article  PubMed  Google Scholar 

  29. Smith JW, Fortner JG, Burt M (1992) Resection of hepatic and pulmonary metastases from colorectal cancer. Surg Oncol 1(6):399–404

    Article  CAS  PubMed  Google Scholar 

  30. DeMatteo RP et al (2000) Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg 4(2):178–184

    Article  CAS  PubMed  Google Scholar 

  31. Melendez JA et al (1998) Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg 187(6):620–625

    Article  CAS  PubMed  Google Scholar 

  32. Fong Y et al (2000) Hand-assisted laparoscopic liver resection: lessons from an initial experience. Arch Surg 135(7):854–859

    Article  CAS  PubMed  Google Scholar 

  33. Koffron AJ et al. (2007) Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg 246(3): 385–392 (discussion 392-4)

    Google Scholar 

  34. Potter MW et al (2000) A critical appraisal of laparoscopic staging in hepatobiliary and pancreatic malignancy. Surg Oncol 9(3):103–110

    Article  CAS  PubMed  Google Scholar 

  35. Scheele J et al (1995) Resection of colorectal liver metastases. World J Surg 19(1):59–71

    Article  CAS  PubMed  Google Scholar 

  36. Wagner JS et al (1984) The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 199(5):502–508

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Tomlinson JS et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29):4575–4580

    Article  PubMed  Google Scholar 

  38. Pawlik TM, Schulick RD, Choti MA (2008) Expanding criteria for resectability of colorectal liver metastases. Oncologist 13(1):51–64

    Article  PubMed  Google Scholar 

  39. Azoulay D et al (2000) Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg 232(5):665–672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Simmonds PC et al (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94(7):982–999

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Shoup M et al (2003) Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 7(3):325–330

    Article  PubMed  Google Scholar 

  42. Doci R et al (1991) One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 78(7):797–801

    Article  CAS  PubMed  Google Scholar 

  43. Ekberg H et al (1987) Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 11(4):541–547

    Article  CAS  PubMed  Google Scholar 

  44. Fortner JG et al (1984) Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg 199(3):306–316

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Hughes KS et al (1988) Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Dis Colon Rectum 31(1):1–4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Hughes KS et al (1986) Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 100(2):278–284

    CAS  PubMed  Google Scholar 

  47. Rosen CB et al (1992) Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 216(4): 493–504 (discussion 504-5)

    Google Scholar 

  48. Scheele J et al (1991) Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 110(1):13–29

    CAS  PubMed  Google Scholar 

  49. Zacharias T et al (2004) First and repeat resection of colorectal liver metastases in elderly patients. Ann Surg 240(5):858–865

    Article  PubMed  PubMed Central  Google Scholar 

  50. Reddy SK et al (2007) Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol

    Google Scholar 

  51. D’Angelica M et al (1997) Ninety-six five-year survivors after liver resection for metastatic colorectal cancer. J Am Coll Surg 185(6):554–559

    Article  PubMed  Google Scholar 

  52. Fong Y et al (1994) Repeat hepatic resections for metastatic colorectal cancer. Ann Surg 220(5):657–662

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Adam R et al (1997) Repeat hepatectomy for colorectal liver metastases. Ann Surg 225(1): 51–60 (discussion 60-2)

    Google Scholar 

  54. Petrowsky H et al (2002) Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 235(6):863–871

    Article  PubMed  PubMed Central  Google Scholar 

  55. Colucci G et al (1994) Biochemical modulation of fluorouracil with high dose methotrexate or folinic acid in advanced colorectal cancer patients. Gruppo Oncologico dell’ Italia Meridionale (GOIM). Anticancer Res 14(5B):2157–2162

    CAS  PubMed  Google Scholar 

  56. Saltz LB et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13):905–914

    Article  CAS  PubMed  Google Scholar 

  57. Hoff PM et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19(8):2282–2292

    CAS  PubMed  Google Scholar 

  58. Van Cutsem E et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19(21):4097–4106

    PubMed  Google Scholar 

  59. de Gramont A et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947

    PubMed  Google Scholar 

  60. Goldberg RM et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23–30

    Article  CAS  PubMed  Google Scholar 

  61. NCCN, NCCN Clinical Practice Guidelines in Oncology. 2015

    Google Scholar 

  62. Spano JP et al (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16(1):102–108

    Article  PubMed  Google Scholar 

  63. Bokemeyer C et al (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22(7):1535–1546

    Article  CAS  PubMed  Google Scholar 

  64. Douillard JY et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369(11):1023–1034

    Article  CAS  PubMed  Google Scholar 

  65. Douillard JY et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31):4697–4705

    Article  CAS  PubMed  Google Scholar 

  66. Sorich MJ et al (2015) Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 26(1):13–21

    Article  CAS  PubMed  Google Scholar 

  67. Safaee Ardekani, G et al (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 7(10): e47054

    Google Scholar 

  68. Yuan ZX et al (2013) The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis. PLoS One 8(6):e65995

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Adam R et al (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240(6):1052–1064

    Article  PubMed  PubMed Central  Google Scholar 

  70. Moertel CG (1987) Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 5(10):1502–1522

    CAS  PubMed  Google Scholar 

  71. Norheim I et al (1987) Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg 206(2):115–125

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Shebani KO et al (1999) Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 229(6): 815–21 (discussion 822-3)

    Google Scholar 

  73. Chamberlain RS et al (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190(4):432–445

    Article  CAS  PubMed  Google Scholar 

  74. McEntee GP et al (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108(6):1091–1096

    CAS  PubMed  Google Scholar 

  75. Nguyen SQ et al (2007) Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol 96(5):397–403

    Article  PubMed  Google Scholar 

  76. Moertel CG et al (1994) The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 120(4):302–309

    Article  CAS  PubMed  Google Scholar 

  77. Que FG et al (1995) Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169(1): 36–42 (discussion 42-3)

    Google Scholar 

  78. Sarmiento JM et al (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197(1):29–37

    Article  PubMed  Google Scholar 

  79. Yao KA et al (2001) Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130(4): 677–82 (discussion 682-5)

    Google Scholar 

  80. Touzios JG et al (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241(5): 776–83 (discussion 783-5)

    Google Scholar 

  81. Chung MH et al (2001) Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 130(6):954–962

    Article  CAS  PubMed  Google Scholar 

  82. Coppa J et al (2001) Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplant Proc 33(1–2):1537–1539

    Article  CAS  PubMed  Google Scholar 

  83. Harrison LE et al (1997) Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery 121(6):625–632

    Article  CAS  PubMed  Google Scholar 

  84. Earle SA et al (2006) Hepatectomy enables prolonged survival in select patients with isolated noncolorectal liver metastasis. J Am Coll Surg 203(4):436–446

    Article  PubMed  Google Scholar 

  85. Cordera F et al (2005) Hepatic resection for noncolorectal, nonneuroendocrine metastases. J Gastrointest Surg 9(9):1361–1370

    Article  PubMed  Google Scholar 

  86. Elias D et al (1995) Hepatectomy for liver metastases from breast cancer. Eur J Surg Oncol 21(5):510–513

    Article  CAS  PubMed  Google Scholar 

  87. Foster JH (1978) Survival after liver resection for secondary tumors. Am J Surg 135(3):389–394

    Article  CAS  PubMed  Google Scholar 

  88. Salmon RJ et al (1998) Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol 24(2):127–130

    Article  CAS  PubMed  Google Scholar 

  89. Espat NJ (2006) Reported outcome factors for hepatic metastasectomy. J Gastrointest Surg 10(2):155–160

    Article  PubMed  Google Scholar 

  90. Adson MA et al (1984) Resection of hepatic metastases from colorectal cancer. Arch Surg 119(6):647–651

    Article  CAS  PubMed  Google Scholar 

  91. Fong Y et al (1997) Liver resection for colorectal metastases. J Clin Oncol 15(3):938–946

    CAS  PubMed  Google Scholar 

  92. Jamison RL et al (1997) Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 132(5): 505–10 (discussion 511)

    Google Scholar 

  93. Jenkins LT et al (1997) Hepatic resection for metastatic colorectal cancer. Am Surg 63(7):605–610

    CAS  PubMed  Google Scholar 

  94. Bakalakos EA, Young DC, Martin EW Jr (1998) Radioimmunoguided surgery for patients with liver metastases secondary to colorectal cancer. Ann Surg Oncol 5(7):590–594

    Article  CAS  PubMed  Google Scholar 

  95. Elias D et al (1998) Resection of liver metastases from colorectal cancer: the real impact of the surgical margin. Eur J Surg Oncol 24(3):174–179

    Article  CAS  PubMed  Google Scholar 

  96. Choti MA et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235(6):759–766

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Feinberg School of Medicine, Northwestern University, Evanston, USA

    Ramiro Fernandez & David J. Bentrem

  2. Loyola University Medical Center, Maywood, IL, USA

    Sam G. Pappas

  3. Jesse Brown VA Medical Center, Chicago, IL, USA

    David J. Bentrem

Authors
  1. Ramiro Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sam G. Pappas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David J. Bentrem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sam G. Pappas .

Editor information

Editors and Affiliations

  1. Department of Surgery, Northwestern University, Chicago, Illinois, USA

    David Bentrem

  2. Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois, USA

    Al B. Benson

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Fernandez, R., Pappas, S.G., Bentrem, D.J. (2016). Clinical Features of Metastatic Hepatic Malignancies. In: Bentrem, D., Benson, A. (eds) Gastrointestinal Malignancies. Cancer Treatment and Research. Springer, Cham. https://doi.org/10.1007/978-3-319-34244-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-34244-3_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-34242-9

  • Online ISBN: 978-3-319-34244-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation